CCK1
CCK1[edit | edit source]
CCK1 (Cholecystokinin receptor type 1) is a protein-coding gene that is responsible for encoding the CCK1 receptor. This receptor is a G-protein coupled receptor (GPCR) that is primarily expressed in the gastrointestinal tract and the central nervous system. It plays a crucial role in regulating various physiological processes, including appetite, digestion, and anxiety.
Structure[edit | edit source]
The CCK1 receptor is composed of 428 amino acids and belongs to the class A rhodopsin-like GPCR family. It consists of seven transmembrane helices, an extracellular N-terminus, and an intracellular C-terminus. The extracellular domain of the receptor contains the binding site for its ligand, cholecystokinin (CCK), while the intracellular domain interacts with G-proteins to initiate downstream signaling pathways.
Function[edit | edit source]
The primary function of the CCK1 receptor is to bind with CCK, a peptide hormone released in response to food intake. Upon binding, the receptor activates G-proteins, leading to the activation of various intracellular signaling cascades. These signaling pathways regulate the release of digestive enzymes, gastric acid secretion, and the contraction of smooth muscles in the gastrointestinal tract.
Furthermore, the CCK1 receptor is also involved in the regulation of appetite and satiety. Activation of the receptor in the brain triggers a feeling of fullness, reducing food intake. This mechanism makes the CCK1 receptor a potential target for the development of anti-obesity drugs.
Clinical Significance[edit | edit source]
Mutations or dysregulation of the CCK1 receptor have been associated with various disorders. For example, decreased CCK1 receptor activity has been linked to increased appetite and a higher risk of obesity. On the other hand, overexpression of the receptor has been observed in certain types of cancer, including pancreatic and gastric cancer.
Understanding the role of the CCK1 receptor in these diseases has led to the development of targeted therapies. Researchers are exploring the use of CCK1 receptor antagonists for the treatment of obesity, while CCK1 receptor agonists are being investigated as potential anti-cancer agents.
References[edit | edit source]
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
